Arctic Bioscience — Regulatory Filings 2026

Mar 19, 2026

Arctic Bioscience - New peer-reviewed study shows herring roe phospholipids stimulate anti-inflammatory pathways in cells

Arctic Bioscience - New peer-reviewed study shows herring roe phospholipids stimulate anti-inflammatory pathways in cells

Arctic Bioscience announces that new research on herring roe oil (HRO) and

phospholipid esters from herring roe (PEHeRo) has been accepted for publication

in the Journal of Lipid Research, an internationally recognized scientific

journal in the field of lipid biology.

The study shows that HRO and its phospholipids (PEHeRo) activates the body's own

inflammation-resolving mechanisms by increasing the production of specialized

pro-resolving mediators (SPMs) in human immune cells and in a skin cell model

relevant for psoriasis. SPMs are naturally occurring molecules derived from

omega-3 fatty acids that help the body calm and resolve inflammation.

"We are very pleased to see these results published in a high-quality,

peer-reviewed journal. This reinforces the strong scientific foundation built by

our team. The findings further strengthen our understanding of how our

investigational medicine HRO350 may help the body regulate inflammation, which

is directly relevant for diseases like psoriasis," says CEO Christer L.

Valderhaug.

The study demonstrates that treatment with herring roe phospholipids leads to a

clear increase in several lipid mediator families, including mediators known to

support resolution of inflammation and tissue repair. The results were

consistent across both immune cells and skin cells involved in psoriatic disease

processes.

"This research provides important insight into how HRO350 may work at a cellular

level in psoriasis and generally in immune-mediated diseases. We are especially

encouraged by the consistent activation of inflammation-resolving pathways. This

supports the scientific foundation of our clinical development program," says

Medical Director Runhild Gammelsæter.

HRO350 is currently in development as a potential new oral treatment option for

mild-to-moderate psoriasis, a large patient population in need of therapies with

favourable safety and tolerability profiles.

"Our R&D team has devoted a lot of time and resources to this project, and it is

exciting to see the extracts we produce show targeted biological effects in

state-of-the-art laboratory models," says CTO Daniele Mancinelli.

The research was carried out in collaboration with William Harvey Research

Institute (UK), Nofima (Norway), and Møreforsking (Norway), and was partly

supported by a grant from the Norwegian Research Council (project no. 327953).

Reference:

Ringheim-Bakka TA, Saliani A, Østbye TKK, Mildenberger J, Dooley M, Busygina M,

Pedersen ME, Solberg NT, Dalli J, Gammelsæter R. Herring roe PLs promote SPM

biosynthesis in macrophages and a keratinocyte/fibroblast co-culture as model of

psoriasis. Journal of Lipid Research (2026).

DOI: https://doi.org/10.1016/j.jlr.2026.101016

For further information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.